此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors (RESET-PsO)

2026年11月16日 更新者:Xiangya Hospital of Central South University

Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Trial

This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.

Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.

Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.

研究概览

详细说明

After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.

Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.

A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Yehong Kuang
  • 电话号码:+86 13574171102
  • 邮箱:yh_927@126.com

学习地点

      • Shanghai、中国
        • Shanghai Skin Disease Hospital
    • Hunan
      • Changde、Hunan、中国
        • Changde First People's Hospital
      • Changsha、Hunan、中国
        • The Second Xiangya Hospital of Central South University
      • Changsha、Hunan、中国
        • Xiangya Hospital, Central South University
      • Changsha、Hunan、中国
        • The Third Xiangya Hospital of Central South University
    • Liaoning
      • Dalian、Liaoning、中国
        • Dalian Dermatology Hospital
      • Shenyang、Liaoning、中国
        • Central Hospital Affiliated to Shenyang Medical College

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Participants must meet all of the following criteria:

  1. Understand the study requirements and procedures, voluntarily provide written informed consent, and be willing and able to comply with the protocol.

  2. Be male or female and aged 18 to 75 years, inclusive.

  3. Have a clinical diagnosis of plaque psoriasis that was moderate to severe before starting the current interleukin-17A (IL-17A) inhibitor.

  4. Meet the following prior-treatment and prior-response requirements for secondary treatment failure:

    Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).

    The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.

    A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:

    1. Recorded Psoriasis Area and Severity Index (PASI) scores demonstrate a reduction of at least 90% from the PASI score before starting that IL-17A inhibitor, corresponding to a PASI90 response.
    2. Contemporaneous medical records document a static Physician's Global Assessment (sPGA) or Investigator's Global Assessment (IGA) score of 0 or 1, with these categories corresponding to clear or almost clear on the scale used.
    3. Contemporaneous physician records explicitly document clear or almost clear skin lesions.
    4. Contemporaneous medical records document that the percentage of body surface area affected by psoriasis (BSA) decreased to 1% or less during treatment with the same current IL-17A inhibitor.

    The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.

  5. After achieving at least one of the good-response criteria above, have subsequent worsening while continuing the same IL-17A inhibitor, with PASI ≥3 and sPGA ≥2 at both screening and the Week 0 baseline visit, and an investigator judgment that a change in treatment strategy is needed. The investigator must review the prior response, worsening, and treatment records to confirm their temporal sequence and determine that the current worsening is not primarily attributable to treatment interruption or substantial nonadherence.

  6. Have dyslipidemia with fasting low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and <4.9 mmol/L, without atherosclerotic cardiovascular disease (ASCVD).

  7. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. Male and female participants of reproductive potential must agree to use highly effective contraception throughout the study and for 30 days after the last dose of study drug. Participants must also comply with the contraception requirements for their background IL-17A inhibitor. Any longer contraception periods specified in the applicable prescribing information or investigator's brochure must also be observed.

  8. Be willing to complete the required protocol examinations and assessments. Participation in optional assessments is voluntary, and declining them does not affect eligibility for the main study.

Exclusion Criteria:

Participants meeting any of the following criteria are excluded:

  1. A diagnosis of non-plaque psoriasis at screening or baseline, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.
  2. Severe hypersensitivity to an active ingredient or any excipient of the study drugs.
  3. Concomitant malignancy.
  4. Any previous or current PCSK9-targeted therapy, including PCSK9 monoclonal antibodies or PCSK9-targeting small interfering RNA (siRNA) drugs, such as inclisiran.
  5. Current treatment at screening with other lipid-lowering drugs, such as statins or ezetimibe. Clinically necessary lipid-lowering treatment must not be discontinued to meet study eligibility criteria.
  6. Treatment with a biologic targeting a pathway other than IL-17A, or a small-molecule targeted drug, within 4 weeks before screening.
  7. Clinically significant active disease, such as active tuberculosis or active hepatitis.
  8. Participation in another clinical trial with use of a trial-related drug within 3 months before screening.
  9. Pregnancy, breastfeeding, or planned pregnancy during the study; or unwillingness of a male or female participant to use contraception.
  10. Major surgery within 3 months before screening or planned major surgery during the study.
  11. Renal impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² during screening.
  12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >2 times ULN.
  13. New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction <30%.
  14. Previously or currently diagnosed ASCVD, including coronary heart disease, ischemic stroke, or atherosclerotic peripheral artery disease; or another type of stroke within 3 months before randomization.
  15. A need to promptly initiate, continue, or intensify lipid-lowering drug therapy, based on an assessment of overall ASCVD risk and lipid-lowering treatment needs according to the Chinese Guidelines for Lipid Management (2023), such that treatment should not be delayed during the 16-week controlled treatment period.
  16. Any other condition that, in the investigator's judgment, makes participation inappropriate.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Recaticimab Plus Background IL-17A Inhibitor

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.

Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.

安慰剂比较:Placebo Plus Background IL-17A Inhibitor

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.

Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.

Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of participants achieving PASI75 at Week 16
大体时间:Week 16

PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline.

Week 16

次要结果测量

结果测量
措施说明
大体时间
Mean percentage improvement from baseline in sPGA × BSA at Week 16
大体时间:Baseline (Week 0) and Week 16

sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value.

Baseline (Week 0) and Week 16
Mean change from baseline in PASI score
大体时间:Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease.

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Mean percentage improvement from baseline in PASI score
大体时间:Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement.

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI50
大体时间:Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI90
大体时间:Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI100
大体时间:Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with a 100% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants with sPGA 0 or 1
大体时间:Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in skin itch Numeric Rating Scale score
大体时间:Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch).

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in Dermatology Life Quality Index score
大体时间:Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36

Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life.

Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
Percentage change from baseline in low-density lipoprotein cholesterol
大体时间:Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32

Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement.

Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
Participants with treatment-emergent adverse events
大体时间:From the first study dose through Week 36

Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit.

From the first study dose through Week 36

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月10日

初级完成 (估计的)

2028年4月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年11月16日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅